Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

NCT06680752 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
MDS (Myelodysplastic Syndrome)

Interventions

BIOLOGICAL: ARD103
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

ARCE Therapeutics, Inc.